Adjunctive dexamethasone implant during vitrectomy with silicone oil for diabetic tractional retinal detachment: a systematic review and exploratory meta-analysis.
Ahmar Jan Qureshi, Ali Shan Hafeez, Hamna Hassan Siddiqui, Ahsab Zaka, Muhammad Riyyan Tariq Tagga, Tooba Munir, Eashel Farooq, Muhammad Bilal, Atiqullah Sadaqat
{"title":"Adjunctive dexamethasone implant during vitrectomy with silicone oil for diabetic tractional retinal detachment: a systematic review and exploratory meta-analysis.","authors":"Ahmar Jan Qureshi, Ali Shan Hafeez, Hamna Hassan Siddiqui, Ahsab Zaka, Muhammad Riyyan Tariq Tagga, Tooba Munir, Eashel Farooq, Muhammad Bilal, Atiqullah Sadaqat","doi":"10.1186/s40942-026-00903-5","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Diabetic tractional retinal detachment (TRD) secondary to proliferative diabetic retinopathy is a vision-threatening complication that may require pars plana vitrectomy in selected cases, particularly when the macula is threatened or detached. Silicone oil tamponade is commonly used in complex cases, although tamponade choice varies according to surgical findings and surgeon preference.</p><p><strong>Objectives: </strong>To evaluate surgical outcomes associated with adjunctive dexamethasone implant during pars plana vitrectomy with silicone oil or heavy silicone oil tamponade for diabetic tractional retinal detachment.</p><p><strong>Methods: </strong>A comprehensive literature search of PubMed, Scopus, Web of Science, and ClinicalTrials.gov was performed from inception through 2025. Randomized and non-randomized comparative studies assessing PPV with silicone oil with or without adjunctive dexamethasone implant were considered. Definitions of postoperative PVR and retinal redetachment were accepted as reported by the original studies; no individual-level imaging or independent photographic regrading was available. The anatomical outcome was an exploratory composite of study-reported postoperative proliferative vitreoretinopathy (PVR) and/or retinal redetachment outcomes. Because definitions and follow-up time points differed across studies, this outcome was not treated as a uniformly graded PVR endpoint. Randomized and non-randomized comparative studies were identified; randomized trials were prioritized for the main analysis, while the non-randomized study was considered separately because of serious risk of bias. Secondary outcomes included best-corrected visual acuity (BCVA), central subfield thickness (CST), ocular hypertension, and postoperative complications. The protocol was prospectively registered in the International Prospective Register of Systematic Reviews (PROSPERO: CRD420261283105) prior to the commencement of the review.</p><p><strong>Results: </strong>Four studies involving 305 eyes were included. In the main randomized-trial analysis, two studies comprising 123 eyes contributed to the exploratory study-reported postoperative proliferative/redetachment composite. The pooled estimate was highly imprecise (RR 0.20, 95% CI 0.00 to 16.06; I² = 0%) and did not provide conclusive evidence of benefit. In an exploratory sensitivity analysis including the non-randomized study, the estimate favored dexamethasone implant, but this analysis was subject to serious risk of bias. BCVA and CST findings were limited by small sample sizes, heterogeneity, and inconsistent reporting. Intraocular-pressure outcomes were not pooled because definitions and assessment time points differed across studies.</p><p><strong>Conclusion: </strong>Current evidence is insufficient to support routine adjunctive dexamethasone implant use during vitrectomy with silicone oil for diabetic tractional retinal detachment. The available studies provide only a hypothesis-generating signal of fewer study-reported postoperative proliferative or redetachment events. Use should remain selective and individualized until adequately powered randomized trials with standardized anatomical outcomes are available.</p><p><strong>Clinical trials number: </strong>Not applicable.</p>","PeriodicalId":14289,"journal":{"name":"International Journal of Retina and Vitreous","volume":" ","pages":""},"PeriodicalIF":3.8000,"publicationDate":"2026-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13679000/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Retina and Vitreous","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s40942-026-00903-5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Diabetic tractional retinal detachment (TRD) secondary to proliferative diabetic retinopathy is a vision-threatening complication that may require pars plana vitrectomy in selected cases, particularly when the macula is threatened or detached. Silicone oil tamponade is commonly used in complex cases, although tamponade choice varies according to surgical findings and surgeon preference.
Objectives: To evaluate surgical outcomes associated with adjunctive dexamethasone implant during pars plana vitrectomy with silicone oil or heavy silicone oil tamponade for diabetic tractional retinal detachment.
Methods: A comprehensive literature search of PubMed, Scopus, Web of Science, and ClinicalTrials.gov was performed from inception through 2025. Randomized and non-randomized comparative studies assessing PPV with silicone oil with or without adjunctive dexamethasone implant were considered. Definitions of postoperative PVR and retinal redetachment were accepted as reported by the original studies; no individual-level imaging or independent photographic regrading was available. The anatomical outcome was an exploratory composite of study-reported postoperative proliferative vitreoretinopathy (PVR) and/or retinal redetachment outcomes. Because definitions and follow-up time points differed across studies, this outcome was not treated as a uniformly graded PVR endpoint. Randomized and non-randomized comparative studies were identified; randomized trials were prioritized for the main analysis, while the non-randomized study was considered separately because of serious risk of bias. Secondary outcomes included best-corrected visual acuity (BCVA), central subfield thickness (CST), ocular hypertension, and postoperative complications. The protocol was prospectively registered in the International Prospective Register of Systematic Reviews (PROSPERO: CRD420261283105) prior to the commencement of the review.
Results: Four studies involving 305 eyes were included. In the main randomized-trial analysis, two studies comprising 123 eyes contributed to the exploratory study-reported postoperative proliferative/redetachment composite. The pooled estimate was highly imprecise (RR 0.20, 95% CI 0.00 to 16.06; I² = 0%) and did not provide conclusive evidence of benefit. In an exploratory sensitivity analysis including the non-randomized study, the estimate favored dexamethasone implant, but this analysis was subject to serious risk of bias. BCVA and CST findings were limited by small sample sizes, heterogeneity, and inconsistent reporting. Intraocular-pressure outcomes were not pooled because definitions and assessment time points differed across studies.
Conclusion: Current evidence is insufficient to support routine adjunctive dexamethasone implant use during vitrectomy with silicone oil for diabetic tractional retinal detachment. The available studies provide only a hypothesis-generating signal of fewer study-reported postoperative proliferative or redetachment events. Use should remain selective and individualized until adequately powered randomized trials with standardized anatomical outcomes are available.
背景:继发于增殖性糖尿病视网膜病变的糖尿病牵引性视网膜脱离(TRD)是一种威胁视力的并发症,在某些情况下可能需要进行玻璃体切除手术,特别是当黄斑受到威胁或脱离时。硅油填塞通常用于复杂病例,尽管填塞的选择根据手术结果和外科医生的偏好而有所不同。目的:评价硅油或重硅油填塞玻璃体切除术治疗糖尿病牵引性视网膜脱离时辅助地塞米松植入的手术效果。方法:全面检索PubMed、Scopus、Web of Science和ClinicalTrials.gov从成立到2025年的文献。随机和非随机比较研究评估了硅油与或不辅助地塞米松植入物的PPV。术后PVR和视网膜再脱离的定义被原始研究报告所接受;没有个人水平的成像或独立的摄影评分。解剖结果是研究报告的术后增殖性玻璃体视网膜病变(PVR)和/或视网膜再脱离结果的探索性综合结果。由于不同研究的定义和随访时间点不同,该结果未被视为统一分级的PVR终点。确定了随机和非随机比较研究;随机试验优先用于主分析,而非随机研究因存在严重的偏倚风险而单独考虑。次要结局包括最佳矫正视力(BCVA)、中心亚野厚度(CST)、高眼压和术后并发症。在审查开始前,该方案已在国际前瞻性系统评价登记册(PROSPERO: CRD420261283105)进行前瞻性注册。结果:纳入4项研究,涉及305只眼睛。在主要的随机试验分析中,包括123只眼睛的两项研究为探索性研究报告的术后增殖/再脱离复合研究做出了贡献。合并估计高度不精确(RR 0.20, 95% CI 0.00至16.06;I²= 0%),并且没有提供获益的确凿证据。在包括非随机研究的探索性敏感性分析中,估计偏向地塞米松植入物,但该分析存在严重的偏倚风险。BCVA和CST的研究结果受到样本量小、异质性和报道不一致的限制。由于不同研究的定义和评估时间点不同,因此没有汇总眼内压结果。结论:目前的证据不足以支持常规辅助地塞米松植入硅油玻璃体切除术治疗糖尿病牵引性视网膜脱离。现有的研究仅提供了较少研究报告的术后增生或再脱离事件的假设生成信号。使用应保持选择性和个体化,直到有足够的随机试验和标准化的解剖结果可用。临床试验号:不适用。
期刊介绍:
International Journal of Retina and Vitreous focuses on the ophthalmic subspecialty of vitreoretinal disorders. The journal presents original articles on new approaches to diagnosis, outcomes of clinical trials, innovations in pharmacological therapy and surgical techniques, as well as basic science advances that impact clinical practice. Topical areas include, but are not limited to: -Imaging of the retina, choroid and vitreous -Innovations in optical coherence tomography (OCT) -Small-gauge vitrectomy, retinal detachment, chromovitrectomy -Electroretinography (ERG), microperimetry, other functional tests -Intraocular tumors -Retinal pharmacotherapy & drug delivery -Diabetic retinopathy & other vascular diseases -Age-related macular degeneration (AMD) & other macular entities